Generic SPECTINOMYCIN HYDROCHLORIDE INN equivalents, pharmaceutical patent and freedom to operate

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 2
Merz Pharmaceuticals GmbH	Phase 2
Universita di Verona	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TROBICIN	spectinomycin hydrochloride	INJECTABLE;INJECTION	050347-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pfizer	TROBICIN	spectinomycin hydrochloride	INJECTABLE;INJECTION	050347-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 8, 2026

Spectinomycin hydrochloride is a mature injectable aminocyclitol antibiotic with limited commercial scale. Its original branded product, Trobicin, has lost all meaningful patent and regulatory exclusivity. Current demand is driven by public-health procurement, treatment of selected gonorrhea cases, antimicrobial-resistance programs, and availability in markets where newer recommended therapies are unsuitable or inaccessible. Public financial data do not identify standalone revenue for spectinomycin hydrochloride, and the product is not a significant revenue contributor for major multinational pharmaceutical companies.

What is the current market position of spectinomycin hydrochloride?

Spectinomycin hydrochloride is primarily marketed as an intramuscular injection for treatment of uncomplicated gonorrhea caused by susceptible strains of Neisseria gonorrhoeae. It is not a mass-market oral antibiotic and has limited use in hospital formularies.

Market factor	Current position
Active ingredient	Spectinomycin hydrochloride
Drug class	Aminocyclitol antibacterial
Primary dosage form	Intramuscular injection
Historical brand	Trobicin
Main indication	Uncomplicated gonorrhea
U.S. commercial status	Original branded product discontinued; not a routine U.S. treatment option
Patent status	Core composition and use patents expired
Exclusivity	No meaningful current U.S. market exclusivity
Primary demand sources	Government procurement, specialty distributors, regional generic markets
Major commercial constraint	Narrow indication and injectable administration
Principal demand catalyst	Resistance or intolerance to first-line gonorrhea therapies

Spectinomycin acts by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit. Its historical value came from activity against gonococci and a relatively favorable tolerability profile. Its commercial role has narrowed because ceftriaxone-based treatment is preferred in current U.S. guidelines and because spectinomycin has limited activity against pharyngeal gonorrhea.

The World Health Organization has retained spectinomycin as an option in certain gonorrhea-treatment settings where local susceptibility, availability, and clinical circumstances support its use. The U.S. Centers for Disease Control and Prevention does not list spectinomycin as a standard available U.S. regimen, citing limited availability and inadequate efficacy for pharyngeal infection [1,2].

When did spectinomycin hydrochloride lose exclusivity?

Spectinomycin hydrochloride lost meaningful exclusivity decades ago. The active pharmaceutical ingredient was introduced in the 1960s, and any original composition-of-matter protection has long expired. The product has no current protection comparable to a modern small-molecule new chemical entity.

Patent and exclusivity timeline

Period	Commercial and legal event
1960s	Spectinomycin identified and developed as an antibacterial agent
1970s	U.S. commercialization of spectinomycin injection under the Trobicin brand
1980s-1990s	Core composition and original-use protection expired or became commercially irrelevant
2000s	Branded U.S. availability declined and was ultimately discontinued
2010s-present	Regional generic and government-procurement supply continued in selected markets
Current	No meaningful patent-based exclusivity identified for the active ingredient

The remaining intellectual-property value is limited to possible manufacturing processes, impurity-control methods, packaging, or specific formulations. Such rights would not restore broad market exclusivity unless they were difficult to design around and commercially essential.

What is the FDA regulatory status of spectinomycin hydrochloride?

The original U.S. product, Trobicin, is no longer a routine commercial treatment in the United States. FDA records and CDC guidance indicate that spectinomycin is not generally available for U.S. gonorrhea treatment [1,3].

The regulatory position differs by jurisdiction. In some countries, spectinomycin hydrochloride remains registered as an injectable prescription antibiotic. Registration does not establish substantial market demand. Commercial activity depends on whether national treatment guidelines include the drug, whether local resistance patterns support use, and whether a qualified manufacturer can maintain supply.

U.S. regulatory considerations

The principal U.S. barriers are commercial availability and clinical positioning rather than patent rights.

No current branded exclusivity protects the product.
The drug is not a preferred first-line therapy for uncomplicated gonorrhea.
Its injectable presentation raises distribution and administration costs.
Limited pharyngeal efficacy reduces its addressable patient population.
A new U.S. sponsor would likely need an abbreviated or other applicable regulatory pathway based on the existing reference product and current regulatory requirements.
Manufacturing, clinical bridging, stability, and supply-chain obligations could be disproportionate to expected U.S. revenue.

What is the Orange Book status of spectinomycin hydrochloride?

Spectinomycin hydrochloride does not have a commercially meaningful Orange Book patent position. The historical Trobicin product is not a current source of enforceable U.S. patent exclusivity.

For a discontinued reference product, the main regulatory issue is whether an applicant could rely on an approved reference product or would need to address FDA requirements applicable to discontinued or otherwise unavailable products. The Orange Book listing, where present, would not create a live patent barrier by itself. Patent protection and regulatory reference-product status are separate issues.

How many patents cover spectinomycin hydrochloride?

No active, broad patent estate is known to protect spectinomycin hydrochloride as a molecule. The principal patent value has expired because the drug is an old antibiotic.

Potentially relevant rights can fall into four categories:

Manufacturing patents covering fermentation, purification, crystallization, or salt formation.
Formulation patents covering injectable stability, excipients, or reconstitution.
Method-of-use patents covering a defined resistant bacterial population or dosing protocol.
Packaging or device patents covering vials, diluents, or delivery systems.

These rights are unlikely to produce meaningful exclusivity unless they are necessary for regulatory approval or materially reduce manufacturing cost. A generic manufacturer can often avoid narrow process claims by using an alternative fermentation or purification route.

How strong is the patent estate for spectinomycin hydrochloride?

The estate is weak from a commercial-exclusivity perspective.

Patent factor	Assessment
Composition-of-matter protection	Expired
Original therapeutic-use protection	Expired
Formulation protection	Limited and potentially design-around
Manufacturing protection	Possible in individual jurisdictions, but generally narrow
Method-of-use protection	Commercially limited
Patent litigation risk	Low relative to modern branded antibiotics
Freedom-to-operate risk	More relevant to manufacturing than sale of the active ingredient

What formulations are protected by spectinomycin patents?

The commercially established formulation is a sterile powder for intramuscular injection that is reconstituted before administration. The formulation is operationally simple compared with long-acting injectables, liposomal products, or complex biologics.

Potential formulation barriers include:

Sterility assurance.
Moisture and thermal stability.
Reconstitution time.
Container-closure integrity.
Compatibility with the diluent.
Control of degradation products.
Consistent potency of the hydrochloride salt.

These technical requirements are important for regulatory approval but do not necessarily create durable intellectual-property protection. A manufacturer can generally pursue a non-infringing injectable presentation if it can meet quality standards and demonstrate pharmaceutical equivalence or another acceptable regulatory basis.

Are there Paragraph IV challenges to spectinomycin hydrochloride?

There is no prominent recent U.S. Paragraph IV litigation landscape associated with spectinomycin hydrochloride. The product’s age, discontinued branded status, and limited commercial value provide little incentive for a high-cost patent challenge.

A Paragraph IV filing would be commercially rational only if:

A viable U.S. reference-product pathway existed.
The applicant could secure a reliable active-ingredient supply.
The sponsor expected sufficient demand from public-health or specialty channels.
A remaining patent claim created an actual launch obstacle.
FDA approval could be obtained without extensive new clinical development.

The more likely U.S. route for a future entrant would involve regulatory and manufacturing execution rather than patent litigation.

Which companies are challenging or supplying spectinomycin hydrochloride?

No major multinational company is publicly positioned as an active U.S. challenger to an incumbent spectinomycin brand. Supply is more likely to come from regional generic manufacturers, contract manufacturers, and government-tender suppliers.

The competitive field is fragmented across:

Manufacturers of sterile injectable antibiotics.
API producers in China and India.
Regional pharmaceutical companies holding national registrations.
Public-sector procurement contractors.
Specialty distributors serving sexually transmitted infection programs.

Supplier concentration can be higher than the number of visible finished-dose brands suggests. A manufacturer may produce the API while another company owns the local registration and a third handles government distribution.

What is the financial trajectory for spectinomycin hydrochloride?

Spectinomycin hydrochloride has a low-growth, low-visibility financial profile. Its revenue trajectory is shaped by intermittent procurement rather than expanding chronic or specialty demand.

Revenue profile

Financial variable	Expected market pattern
Global revenue disclosure	Generally unavailable on a standalone basis
Revenue growth	Flat, volatile, or tender-dependent
Pricing	Generic and procurement-driven
Gross margin	Dependent on sterile manufacturing and volume
Demand concentration	High concentration in selected countries and public programs
Commercial investment	Low
Sales force requirement	Limited; institutional and tender channels dominate
Forecast visibility	Weak because purchases can be episodic
Upside potential	Primarily supply shortages, resistance, or guideline changes

No public company is widely known to report spectinomycin hydrochloride as a separate revenue line. Financial analysis therefore requires a bottom-up approach based on market volume, tender pricing, product registrations, and manufacturing capacity rather than company-reported sales.

The product can remain economically viable at modest volume because the active ingredient is old and clinical development costs are sunk. Profitability is more sensitive to batch size, sterile-filling costs, quality failures, and tender pricing than to marketing expenditure.

What factors are driving market demand?

Antimicrobial resistance

Resistance to older gonorrhea therapies has changed the commercial role of spectinomycin. It can retain value as a reserve option where susceptibility is preserved, but resistance surveillance is essential. Gonococcal treatment guidelines increasingly favor ceftriaxone, while concerns about emerging resistance support maintaining alternative agents and supply sources [1,2].

Limited treatment alternatives

Spectinomycin may be used when patients cannot receive preferred cephalosporins, when local resistance data support its use, or when supply constraints affect first-line products. Its value increases during shortages but falls when ceftriaxone and other recommended treatments are reliably available.

Geographic variation

Demand is likely stronger in countries where:

Spectinomycin remains included in national guidelines.
Injectable treatment is common.
Public-health procurement is centralized.
Local resistance patterns support the drug.
Access to ceftriaxone or newer alternatives is inconsistent.

Demand is weak in markets that have removed spectinomycin from treatment protocols or lack registered products.

Administration limitations

The product requires intramuscular administration. That limits use in retail pharmacy settings and makes demand dependent on clinics, hospitals, sexually transmitted infection centers, and public-health programs.

How does spectinomycin compare with ceftriaxone and gentamicin?

Attribute	Spectinomycin	Ceftriaxone	Gentamicin
Drug class	Aminocyclitol	Third-generation cephalosporin	Aminoglycoside
Typical role	Alternative or reserve option	Preferred treatment in major guidelines	Alternative in selected settings
Administration	Intramuscular	Intramuscular	Intramuscular
Pharyngeal efficacy	Limited	Preferred relative to alternatives	Lower or uncertain
Patent position	Expired	Mostly mature, but product-specific rights may vary	Expired
Market scale	Small and regional	Large global public-health market	Larger than spectinomycin in some settings
Commercial outlook	Stable niche or declining	Stronger demand, subject to resistance and supply	Alternative-driven

Ceftriaxone has the strongest clinical and commercial position because it is the preferred treatment in CDC guidance. Gentamicin has greater contemporary guideline relevance in some alternative regimens than spectinomycin, particularly in the United States [1].

What generic launch scenarios exist for spectinomycin hydrochloride?

Scenario 1: Regional continuation

Existing manufacturers maintain supply through national registrations and tenders. This is the most probable scenario. Revenue remains modest and concentrated.

Scenario 2: Supply-led price expansion

A manufacturing disruption affecting competing injectable antibiotics creates temporary demand and price increases. The effect would likely be episodic rather than structural.

Scenario 3: Public-health reactivation

A country or international procurement program adds spectinomycin as a reserve treatment because of resistance or shortages. This could increase volume but would require guideline and regulatory support.

Scenario 4: U.S. re-entry

A sponsor develops or acquires a U.S. product. The opportunity would be constrained by limited clinical use, the absence of a large branded market, and manufacturing economics. Patent risk would be low, but regulatory and commercial execution risk would be high.

Scenario 5: Further decline

Guidelines continue to favor ceftriaxone and gentamicin, while supply becomes less reliable. The market contracts to isolated countries and emergency procurement.

What manufacturing and intellectual-property barriers exist?

Manufacturing is a more material barrier than patents. A potential supplier must manage:

Qualified spectinomycin hydrochloride API sources.
Sterile powder filling.
Microbiological control.
Validated reconstitution performance.
Stability under regional distribution conditions.
Compliance with current good manufacturing practice requirements.
Continuity of supply for low-volume batches.

The economics favor manufacturers that already operate sterile-injectable facilities. A company building a dedicated facility for spectinomycin alone would face poor asset utilization. Contract manufacturing or portfolio production is more commercially rational.

What patent litigation and settlement agreements affect the market?

No significant current U.S. patent litigation or settlement agreement is publicly associated with spectinomycin hydrochloride. The product is too mature and commercially narrow to support the type of branded-generic litigation seen with high-revenue drugs.

Commercial disputes are more likely to concern:

API quality.
Product recalls.
Registration ownership.
Tender awards.
Distribution rights.
Supply interruptions.
Good manufacturing practice compliance.

Key Takeaways

Spectinomycin hydrochloride is a mature, low-revenue injectable antibiotic with no meaningful remaining composition-of-matter exclusivity.
Trobicin’s historical U.S. franchise no longer defines an active branded market.
The product is not a preferred U.S. gonorrhea treatment and has limited usefulness for pharyngeal infection.
Current demand is regional, tender-driven, and dependent on antimicrobial-resistance policy.
Patent litigation and Paragraph IV risk are low.
Manufacturing capacity, sterile-filling economics, regulatory registration, and supply reliability matter more than intellectual property.
Standalone revenue is generally not disclosed, so market sizing depends on procurement and supplier-level data.
The most likely financial outcome is a stable but narrow niche, with episodic upside during shortages or resistance-driven treatment changes.

FAQs

Is spectinomycin hydrochloride still manufactured?

Yes. Regional manufacturers and government-oriented suppliers continue to produce or register spectinomycin hydrochloride in selected markets, although availability is not uniform.

Is spectinomycin hydrochloride available in the United States?

It is not generally available as a routine U.S. gonorrhea treatment. CDC guidance favors ceftriaxone and identifies other alternatives where appropriate [1].

Does spectinomycin hydrochloride have active patents?

No broad active patent protecting the old molecule is generally relevant. Any remaining rights would more likely concern manufacturing, formulation, packaging, or a jurisdiction-specific use.

Can spectinomycin treat pharyngeal gonorrhea?

Its pharyngeal efficacy is limited, which is a major reason it is not preferred when infection may involve the pharynx [1,2].

Is spectinomycin hydrochloride commercially attractive for a generic manufacturer?

It can be attractive for an existing sterile-injectable manufacturer with access to public tenders and regional registrations. It is less attractive as a stand-alone investment because demand is narrow and price competition is strong.

References

Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187. https://www.cdc.gov/std/treatment-guidelines/default.htm
World Health Organization. (2024). WHO guidelines for the treatment of Neisseria gonorrhoeae. World Health Organization. https://www.who.int/publications
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and discontinued drug products. https://www.accessdata.fda.gov/scripts/cder/daf/

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	172
Clinical Trials:	3
DailyMed Link:	SPECTINOMYCIN HYDROCHLORIDE at DailyMed

Summary for SPECTINOMYCIN HYDROCHLORIDE

Recent Clinical Trials for SPECTINOMYCIN HYDROCHLORIDE

Medical Subject Heading (MeSH) Categories for SPECTINOMYCIN HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) Classes for SPECTINOMYCIN HYDROCHLORIDE